Maralixibat chloride (SHP625; LUM001; SHP-625; LUM-001; lopixibat; Livmarli) is a potent ileal bile acid transporter inhibitor that has gained FDA approval in 2021 for treatment of cholestatic pruritus associated with Alagille syndrome.

纯度：≥98%

CAS：228113-66-4